EX	PRESS	MAII	. NO. EV336654351U	JS			-			neet 2 c	of <u>3</u>	
FCRM PTO-1449 (REV.7-80)			U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY, DOCKET NO. 980034.417C1	APPLICATION NO. 09/960,264					
POLIDITI CLIDDI PARENTAI						980034.417C1 09/900,204 APPLICANTS						
FOURTH SUPPLEMENTAL REFORMATION DISCLOSURE STATEMENT												
	(Use several sheets if necessary)				FILING DATE			ı	IP ART UNIT			
11	2 1 2004					September 20, 2001 1651						
PAI	<u>ئ</u> كام	*		U.S.	PATENT	DOCUMENTS	·					
TRAI	AMINAR		DOCUMENT NUMBER	DATE		NAME	CLASS		SUBCLASS	FILING IF APPRO		
V	,L_	ВА	6,544,788	04/08/03	Singh		435		383			
	<u>L</u>	вв	2001/0031253	10/18/01	Gruenberg	g	424		93.1			
•		вс	2002/0090362	07/11/02	Strauss		424		93.21			
,		BD	2002/0182730	12/05/02	Gruenber	435		375				
		BE	2003/0039650	02/27/03	Gruenber	g	424		144.1			
		BF	2003/0134341	07/17/03	Gruenber	g	435		7.21			
		BG	2003/0134415	07/17/03	Gruenber	g	435		372			
		вн	2003/0170238	09/11/03	Gruenber	g	424		144.1			
	,	ВІ	2003/0175242	09/18/03	Gruenber	g	424		93.2		÷	
•	<u> </u>	ВЈ	2003/0175272	09/18/03	Gruenber	g	424		144.1			
				FOREI	GN PATE	NT DOCUMENTS						
			DOCUMENT NUMBER	DATE		COUNTRY				TRANS	NO	
w		вк	WO 03/025158	03/27/03	WIPO							
	1	BL	WO 03/034820	05/01/03	WIPO							
		ВМ	WO 03/043643	05/30/03	WIPO							
P		BN	WO 03/077658	09/25/03	WIPO							
		ــــــــــــــــــــــــــــــــــــــ	OTHE	R PRIOR A	RT (Including	Author, Title, Date, Pertinent Pa	uges Etc				<u> </u>	
	_	I .							Effector ar	nd Men	norv T	
1	Vsc	ВО	Lanzavecchia, A., "The Role of Dendritic Cells in the Generation of Effector and Memory T Cell Responses," from <i>The Midwinter Conference of Immunologists</i> , January 22-25, 2000,									
	Ì		•	•		ol.org/Midwinter00/ses	_		-	-		
BP Li, Q. et al., "Expanded Tumor-reactive CD4 ⁺ T-Cell Responses to Human Cance							cers In	duced				
	by Secondary Anti-CD3/Anti-CD28 Activat				Activation," Clinical	Cance	r Res	search 5: 4	161-46	9,		
	1,_	<u> </u>	February 199							_		
	Li, Q. et al., "Immunological Effects of BCG as an Adjuvant in Autolog Vaccines," Clinical Immunology 94(1): 64-72, January 2000.				ogous Tui	nor						
EX	AMINI	L ER		unical IMM	unology 94	DATE CONSIDERED						
			LANKFORD			<u> </u>	725					
* E.	XAMIN					nformance with MPEP 609. Draw with next communication to appli		ough ci	tation if not in			

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE			ATTY. DOCKET NO.			APPLICATION NO.				
(REV.7-80)		PATENT AND TRADEMARK OFFICE						09/9	09/960,264 OIP			
		OURTH SUPPLEM			APPLICANTS				/		જો	
INFO)RM	TION DISCLOSURE STATEMENT (Use several sheets if necessary)			Ronald Berenson et al.				APP 2			
									ROUP ART PHIT APR 2 1 2004			
				September 20, 2001 1651						- Š		
			U.S.	PATENT 1	DOCUMENT	S			~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	ADEMP	EW Cr	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME			CLASS		SUBCLASS	FILING IF APPRO		
LBL	CA	2003/0194395	10/16/03	Gruenberg et al.			424		93.7			
	СВ											
•	сс											
	CD											
	CE											
	CF											
	CG											
	СН											
	CI											
	CJ											
			FORE	IGN PATE	NT DOCUME	ENTS					v	
		DOCUMENT NUMBER	DATE		(COUNTRY				TRANSLATION YES NO		
	СК									123		
•	CL											
	CM								·····	<u> </u>		
	CN										<u> </u>	
										-	ļ	
	со	<u> </u>					 ,			<u> </u>]	
					Author, Title, Date							
	CP				ice Exhibit A							
LBV					iprocal Decre						D4 ⁺ T	
		Cell Activity	," The Jour	nal of Immi	inology 148(2	2): 648-65	5, Jar	nuary	15, 1992.			
	cq											
	CR											
EVAMBI	<u> </u>		**************************************		DATE CON	SIDEDED				_		
EXAMINER		LANKFOR	_		DATE CON				·			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).												